Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJL; DAPA-CKD and DAPA-HF Trial Committees and Investigators.
Rossing P, et al. Among authors: jhund ps.
Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34. doi: 10.1016/S2213-8587(21)00295-3. Epub 2021 Nov 29.
Lancet Diabetes Endocrinol. 2022.
PMID: 34856173
Free article.